Hills Bank & Trust’s ImmunityBio IBRX Stock Holding History

Hills Bank & Trust’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$545K	Hold	62,285	–	–	0.02%	225
2026 Q1	$478K	Buy	62,285 +21,340	+52%	+$146K	0.02%	217
2025 Q4	$81.1K	Buy	40,945 +16,762	+69%	+$38K	﹤0.01%	339
2025 Q3	$59.5K	Buy	+24,183	New	+$62.3K	﹤0.01%	323

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hills Bank & Trust's IBRX Position: Q2 2026 in Review

Hills Bank & Trust held its ImmunityBio (IBRX) position steady in Q2 2026 at 62,285 shares worth $545K. The position accounts for 0.02% of the portfolio, ranked #225.

Hills Bank & Trust first reported a position in IBRX in Q3 2025 and has held it in 4 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Hills Bank & Trust held 62,285 shares of ImmunityBio worth $545K as of Q2 2026.
Hills Bank & Trust left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up 0.02% of Hills Bank & Trust's portfolio in Q2 2026, its #225 holding.
Hills Bank & Trust first reported a position in ImmunityBio in Q3 2025 and has held it in 4 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Hills Bank & Trust's 13F filing for Q2 2026, filed 10 Aug 2026.